EUCTR2019-004789-17-FR进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis - A study to assess the efficacy and safety of nemolizumab in subjects with prurigo nodularis
Galderma S.A.0 个研究点目标入组 240 人开始时间: 2020年4月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female and aged =18 years at the time of screening;
- •2. Clinical diagnosis of PN for at least 6 months with:
- •Pruriginous nodular lesions on upper limbs, trunk, and/or lower limbs;
- •At least 20 nodules on the entire body with a bilateral distribution
- •3. IGA score = 3 (based on the IGA scale ranging from 0 to 4, in which 3 is moderate and 4 is severe) at both the screening and baseline visits;
- •4. Severe pruritus defined as follows on the PP NRS:
- •At the screening visit (Visit 1): PP NRS score is = 7.0 for the 24-hour period immediately preceding the screening visit;
- •At the baseline visit (Visit 2): Mean of the daily intensity of the PP NRS score is = 7.0 over the previous week;
- •5. Female subjects of childbearing potential must agree to use at least 1 adequate and approved method of contraception throughout the study and for 12 weeks after the last study drug injection. Adequate and approved methods of contraception applicable for the subject and/or her partner are defined below:
- •True abstinence, when in line with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception;
- •Progestogen-only oral hormonal contraception;
- •Combination of male condom with cap, diaphragm, or sponge with spermicide (double barrier methods);
- •Combined (estrogen- and progestogen-containing) oral, intravaginal, or transdermal hormonal contraception;
- •Injectable or implanted hormonal contraception;
- •Intrauterine devices;
- •Bilateral tubal ligation or tube insert (such as the Essure system) at least 3 months before the study;
- •Vasectomy of male partner at least 3 months before the study
- •6. Female subjects of non-childbearing potential must meet 1 of the following criteria:
- •Absence of menstrual bleeding for 1 year prior to screening without any other medical reason;
- •Documented hysterectomy or bilateral oophorectomy at least 3 months before the study;
- •7. Subject is willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol, including daily diary recordings by the subject using an electronic handheld device provided for this study.
- •8. Read, understood and signed an informed consent form (ICF) before any investigational procedure(s) are performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 198
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 42
排除标准
- •1. Body weight < 30 kg;
- •2. Chronic pruritus resulting from another active condition other than PN, such as but not limited to scabies, lichen simplex chronicus, psoriasis, atopic dermatitis, contact dermatitis, acne, folliculitis, lichen planus, habitual picking/excoriation disorder, sporotrichosis, bullous autoimmune disease, end-stage renal disease, or cholestatic liver disease (eg, primary biliary cirrhosis);
- •3. Unilateral lesions of prurigo (eg, only one arm affected);
- •4. History of or current confounding skin condition (eg, Netherton syndrome, cutaneous T-cell lymphoma [mycosis fungoides or Sezary syndrome], chronic actinic dermatitis, dermatitis herpetiformis)
- •5. Subjects meeting 1 or more of the following criteria at screening or baseline:
- •- Had an exacerbation of asthma requiring hospitalization in the preceding 12 months;
- •- Reporting asthma that has not been well-controlled (ie, symptoms occurring on > 2 days per week, nighttime awakenings 2 or more times per week, or some interference with normal activities) during the preceding 3 months;
- •- Asthma Control Test = 19 (only for subjects with a history of asthma)
- •- Peak expiratory flow < 80% of the predicted value.
- •6. Subjects with a current medical history of chronic obstructive pulmonary disease and/or chronic bronchitis;
- •7. Cutaneous infection within 1 week before the screening visit or any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 1 week before the screening visit. Subjects may be rescreened once the infection has resolved;
- •8. Positive serology results (hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb], hepatitis C antibody, or human immunodeficiency virus antibody) at the screening visit;
- •9. Requiring rescue therapy for PN during the screening period or expected to require rescue therapy within 4 weeks following the baseline visit;
- •10. Subjects with active atopic dermatitis (signs and symptoms other than dry skin) in the last 3 months;
- •11. Neuropathic and psychogenic pruritus such as but not limited to notalgia paresthetica, brachioradial pruritus, small fiber neuropathy, skin picking syndrome, or delusional parasitosis;
- •12. Having received any of the treatments in the table reported in the protocol within the specified timeframe before the baseline visit;
- •13. Previous participation in a clinical study with nemolizumab;
- •14. Pregnant women (positive serum pregnancy test result at the screening visit or positive urine pregnancy test at the baseline visit), breastfeeding women, or women planning a pregnancy during the clinical study;
- •15. History of lymphoproliferative disease or history of malignancy of any organ system within the last 5 years, except for:
- •- Basal cell carcinoma, squamous cell carcinoma in situ (Bowen’s disease), or carcinomas in situ of the cervix that have been treated and have no evidence of recurrence in the last 12 weeks before the screening visit, or;
- •- Actinic keratoses that have been treated
- •16. History of hypersensitivity (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody) or to any of the study drug excipients;
- •17. Known active or latent tuberculosis infection;
- •18. Known or suspected immunosuppression or unusually frequent, recurrent, severe, or prolonged infections as per investigator judgment;
- •19. Any medical or psychological condition or any clinically relevant laboratory abnormalities, such a
研究者
相似试验
进行中（未招募）
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中（未招募）
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placeboEUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中（未招募）
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82